Background/Aim: Management of dyspepsia may differ between countries. In Japan, Helicobacter pylori infection should be considered because of the high prevalence of the infection and the related diseases. I tried to propose an algorithm for stepwise diagnosis and treatment from uninvestigated dyspepsia to functional dyspepsia in clinical practice in Japan. Methods: A proposal was made from my personal review of published studies. Results: A 4-step algorithm was proposed. In the first step, organic, systemic or metabolic diseases are excluded and nonulcer dyspepsia (NUD) is diagnosed. The second step is to test and treat H. pylori infection for NUD patients. In the third step, proton pump inhibitor (PPI)-responsive NUD is discriminated by PPI. Nonresponsive patients in the third step are diagnosed as having PPI-resistant NUD. In the fourth step, functional dyspepsia is diagnosed with the Rome III questionnaire. In this algorithm, it is not necessary to do special function tests for functional gastrointestinal disorders. Treatment options are automatically restricted in each step. Conclusions: The proposed 4-step algorithm may be useful in clinical practice for the diagnosis from uninvestigated dyspepsia to functional dyspepsia in Japan. With this stepwise algorithm, treatment options are restricted in each step and the management of dyspepsia may be easier.

Journal Section:
Paper
Keywords:
Dyspepsia, Algorithm, Helicobacter pylori, Gastroesophageal reflux disease, Functional gastrointestinal disorder, Nonerosive gastroesophageal reflux disease, Proton pump inhibitor, Prokinetics, H2 receptor antagonist
1.
Talley NJ; American Gastroenterological Association: American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005;129:1753–1755.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2005.09.019
2.
Talley NJ, Vakil NB, Moayyedi P: American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756–1780.
[PubMed]
https://doi.org/10.1053%2Fj.gastro.2005.09.020
3.
Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ: Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007;56:772–781.
[PubMed]
https://doi.org/10.1136%2Fgut.2006.101634
4.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders; in Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE (eds): ROME III: The Functional Gastrointestinal Disorders, ed 3. McLean, Degnon Associates Inc., 2006, pp 419–486.
5.
Colin-Jones DG: Management of dyspepsia: report of a working party. Lancet 1988;1:576–579.
[PubMed]
6.
Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138–143.
[PubMed]
https://doi.org/10.1002%2Fijc.11680
7.
Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB: Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547–550.
[PubMed]
8.
Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D: Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;2:CD001960.
9.
Talley NJ, Hunt RH: What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997;113(suppl 6):S67–S77.
10.
Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;2:CD002096.
11.
Nakajima S, Inoue K: Consensus on the requirements in considering eradication therapy to Helicobacter pylori infection for the patients whose diseases are not approved to eradicate by medical insurance. Japn J Helicobacter Res 2007;9:75–76.
12.
Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S, Lin SR, Wong BC, Chan FK, Rani AA, Bak YT, Sollano J, Ho KY, Manatsathit S: Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008;23:8–22.
[PubMed]
https://doi.org/10.1111%2Fj.1440-1746.2008.05314.x
13.
Lee KJ, Vos R, Janssens J, Tack J: Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol 2004;286:G278–G284.
[PubMed]
https://doi.org/10.1152%2Fajpgi.00086.2003
14.
Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD: Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:59–66.
[PubMed]
https://doi.org/10.1046%2Fj.1365-2036.1999.00429.x
15.
Wilson JA, Vela MF: New esophageal function testing (impedance, Bravo pH monitoring, and high-resolution manometry): clinical relevance. Curr Gastroenterol Rep 2008;10:222–230.
[PubMed]
https://doi.org/10.1007%2Fs11894-008-0047-2
16.
Thompson WG, Drossman DA, Talley NJ, Walker L, Whitehead WE; Questionnaire Subcomittee: Rome III diagnostic questionnaire for the adult functional GI disorders (including alarm questions) and scoring algorithm; in Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE (eds): ROME III: The Functional Gastrointestinal Disorders, ed 3. McLean, Degnon Associates Inc., 2006, pp 917–951.
17.
Nakajima S, Fujiyama Y: Preliminary evaluation of the Rome III diagnostic questionnaire for the Japanese adult functional gastrointestinal disorders (FGIDs) utilizing the automated analysis program made by the authors. Shoukakan Undou 2008;10:5–8.
18.
Drossman DA: The functional gastrointestinal disorders and the Rome II process; in Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (eds): ROME II: The Functional Gastrointestinal Disorders, ed 2. McLean, Degnon Associates Inc., 2000, pp 1–29.
19.
Nakajima S: The spectra of functional gastrointestinal disorders (FGIDs) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire. J Gastroenterol Hepatol 2008 (suppl), in press.
20.
Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, Tanaka S, Chayama K, Haruma K: Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007;22:1566–1570.
[PubMed]
https://doi.org/10.1111%2Fj.1440-1746.2006.04723.x
21.
Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005;2:CD002301.
22.
Oikawa T, Ito G, Koyama H, Hanawa T: Prokinetic effect of a Kampo medicine, Hange-koboku-to (Banxia-houpo-tang), on patients with functional dyspepsia. Phytomedicine 2005;12:730–734.
[PubMed]
https://doi.org/10.1016%2Fj.phymed.2005.03.001
23.
Tatsuta M, Iishi H: Effect of treatment with liu-jun-zi-tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther 1993;7:459–462.
[PubMed]
https://doi.org/10.1111%2Fj.1365-2036.1993.tb00120.x
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.